Literature DB >> 25901069

Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload.

Gabriele G Schiattarella1, Joseph A Hill2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25901069      PMCID： PMC4408778          DOI： 10.1161/CIRCULATIONAHA.115.013894

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  136 in total

Review 1.  Cardiac plasticity.

Authors:  Joseph A Hill; Eric N Olson
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

2.  Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.

Authors:  Yongli Kong; Paul Tannous; Guangrong Lu; Kambeez Berenji; Beverly A Rothermel; Eric N Olson; Joseph A Hill
Journal:  Circulation       Date:  2006-05-30       Impact factor: 29.690

Review 3.  The Anrep effect: 100 years later.

Authors:  Horacio E Cingolani; Néstor G Pérez; Oscar H Cingolani; Irene L Ennis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-11-16       Impact factor: 4.733

Review 4.  NADPH oxidases in cardiovascular health and disease.

Authors:  Alison C Cave; Alison C Brewer; Anilkumar Narayanapanicker; Robin Ray; David J Grieve; Simon Walker; Ajay M Shah
Journal:  Antioxid Redox Signal       Date:  2006 May-Jun       Impact factor: 8.401

Review 5.  Hypertrophic reprogramming of the left ventricle: translation to the ECG.

Authors:  Joseph A Hill
Journal:  J Electrocardiol       Date:  2012-09-19       Impact factor: 1.438

6.  Myofibroblasts induce ectopic activity in cardiac tissue.

Authors:  Michele Miragoli; Nicolò Salvarani; Stephan Rohr
Journal:  Circ Res       Date:  2007-09-13       Impact factor: 17.367

7.  Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy.

Authors:  Katherine C Wu; Robert G Weiss; David R Thiemann; Kakuya Kitagawa; André Schmidt; Darshan Dalal; Shenghan Lai; David A Bluemke; Gary Gerstenblith; Eduardo Marbán; Gordon F Tomaselli; João A C Lima
Journal:  J Am Coll Cardiol       Date:  2008-06-24       Impact factor: 24.094

Review 8.  Endothelial dysfunction in heart failure.

Authors:  Johann Bauersachs; Julian D Widder
Journal:  Pharmacol Rep       Date:  2008 Jan-Feb       Impact factor: 3.024

9.  Osteopontin expression of circulating T cells and plasma osteopontin levels are increased in relation to severity of heart failure.

Authors:  Hirofumi Soejima; Atsushi Irie; Takashi Fukunaga; Yoko Oe; Sunao Kojima; Koichi Kaikita; Hiroaki Kawano; Seigo Sugiyama; Michihiro Yoshimura; Hideki Kishikawa; Yasuharu Nishimura; Hisao Ogawa
Journal:  Circ J       Date:  2007-12       Impact factor: 2.993

Review 10.  Histone deacetylase inhibition in the treatment of heart disease.

Authors:  Jeff M Berry; Dian J Cao; Beverly A Rothermel; Joseph A Hill
Journal:  Expert Opin Drug Saf       Date:  2008-01       Impact factor: 4.250
View more
  62 in total

Review 1.  Atrophied cardiomyocytes and their potential for rescue and recovery of ventricular function.

Authors:  Mark R Heckle; David M Flatt; Yao Sun; Salvatore Mancarella; Tony N Marion; Ivan C Gerling; Karl T Weber
Journal:  Heart Fail Rev       Date:  2016-03       Impact factor: 4.214

Review 2.  The nonepigenetic role for small molecule histone deacetylase inhibitors in the regulation of cardiac function.

Authors:  Samantha S Romanick; Bradley S Ferguson
Journal:  Future Med Chem       Date:  2019-06-04       Impact factor: 3.808

3.  "Sensing Danger": A New Player in the Innate Immune Response During Cardiac Pressure Overload.

Authors:  Andrew N Carley; E Douglas Lewandowski
Journal:  Circulation       Date:  2020-12-07       Impact factor: 29.690

Review 4.  Readers, writers, and erasers: chromatin as the whiteboard of heart disease.

Authors:  Thomas G Gillette; Joseph A Hill
Journal:  Circ Res       Date:  2015-03-27       Impact factor: 17.367

5.  Critical role of X-box binding protein 1 in NADPH oxidase 4-triggered cardiac hypertrophy is mediated by receptor interacting protein kinase 1.

Authors:  Li Chen; Mingyue Zhao; Junli Li; Yu Wang; Qinxue Bao; Siyuan Wu; Xueqin Deng; Xiaoju Tang; Wenchao Wu; Xiaojing Liu
Journal:  Cell Cycle       Date:  2016-12-08       Impact factor: 4.534

6.  SLIT3 deficiency attenuates pressure overload-induced cardiac fibrosis and remodeling.

Authors:  Lianghui Gong; Shuyun Wang; Li Shen; Catherine Liu; Mena Shenouda; Baolei Li; Xiaoxiao Liu; John A Shaw; Alan L Wineman; Yifeng Yang; Dingding Xiong; Anne Eichmann; Sylvia M Evans; Stephen J Weiss; Ming-Sing Si
Journal:  JCI Insight       Date:  2020-06-18

7.  SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy.

Authors:  Xiaoqiang Tang; Xiao-Feng Chen; Nan-Yu Wang; Xiao-Man Wang; Shu-Ting Liang; Wei Zheng; Yun-Biao Lu; Xiang Zhao; De-Long Hao; Zhu-Qin Zhang; Ming-Hui Zou; De-Pei Liu; Hou-Zao Chen
Journal:  Circulation       Date:  2017-09-25       Impact factor: 29.690

8.  Rho kinase signaling and cardiac physiology.

Authors:  Yuan Dai; Weijia Luo; Jiang Chang
Journal:  Curr Opin Physiol       Date:  2017-12-13

9.  Signalosome-Regulated Serum Response Factor Phosphorylation Determining Myocyte Growth in Width Versus Length as a Therapeutic Target for Heart Failure.

Authors:  Jinliang Li; Yuliang Tan; Catherine L Passariello; Eliana C Martinez; Michael D Kritzer; Xueyi Li; Xiaofeng Li; Yang Li; Qian Yu; Kenneth Ohgi; Hrishikesh Thakur; John W MacArthur; Jan R Ivey; Y Joseph Woo; Craig A Emter; Kimberly Dodge-Kafka; Michael G Rosenfeld; Michael S Kapiloff
Journal:  Circulation       Date:  2020-09-16       Impact factor: 29.690

10.  The potential role of lysosome-associated membrane protein 3 (LAMP3) on cardiac remodelling.

Authors:  Ding-Sheng Jiang; Xin Yi; Bo Huo; Xin-Xin Liu; Rui Li; Xue-Hai Zhu; Xiang Wei
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.